Physician profile
Vaishali Sinha
NPI 1427462209
$601.36
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $13.73 · 2021: $118 · 2022: $319 · 2023: $133 · 2024: $18.51.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $151.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $102.22 | 2021-2023 | |
| Abbvie INC. | $92.69 | 2022-2024 | Vraylar |
| Pfizer INC. | $52.22 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $49.47 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $45.68 | 2022 | |
| Amgen INC. | $39.49 | 2023 | Prolia, Evenity, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.50 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.81 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.99 | 2023 | Gattex |
| Biohaven Pharmaceuticals, INC. | $21.36 | 2021 | |
| Abbott Laboratories | $20.08 | 2023 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $18.84 | 2022 | |
| Jazz Pharmaceuticals INC. | $17.78 | 2022 | |
| Novo Nordisk INC | $16.72 | 2023 | Wegovy |
| Astrazeneca Pharmaceuticals Lp | $13.11 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $12.87 | 2022 | |
| Grt US Holding, INC. | $11.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vaishali Sinha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.